closer look scienc behind aatd reit buy pt
closer look scienc aatd face
antitrypsin defici aatd appear straight-forward
diseas aatd autosom codomin disord patient
serum level greater consid protect
predomin get diseas respir
contrast patient lower level
risk develop varieti diseas seriou
emphysema result uncheck neutrophil elastas importantli
low serum level suffici induc lung
damag mani healthi aatd subject develop emphysema
lung damag seem occur avail
damag smoke environment exposur similarli
excess exposur neutrophil ne activ
case pneumonia overwhelm emphysema
occur sever approach evalu increas express
activ lung although insight moa
compound evalu vertex hypothes base
experi cystic fibrosi misfold protein similar
approach aatd may pursu
epigenet mechan contribut develop aatd
molecular level least three differ molecular mechan
appear play role develop aatd dna methyl
histon modif result chromatin remodel non-
code rna involv epigenet gene express regul
appear high correl hypo-methyl cpg site
diseas statu epigenet famili
studi demonstr dna methyl associ
presenc sever copd two family-bas cohort compris
subject respect respir crit
non-cod microrna mirna also appear
associ unfold protein respons upr copd
aatd specif decreas cell symptomat
aatd subject silenc mirna result dampen
upr decreas express cytokin monocyt
aatd subject respir crit
although studi promis yet confirm
larger patient set compar copd patient
aatd well
continu next page
definit distribut analyst rate analyst certif disclosur pleas refer page report
mechan affect misfold primari defect respect presenc mutat result
misfold subsequ accumul endoplasm reticulum er hepatocyt genet
variant identifi z-type respons common sever form diseas
homozyg patient ther adv respir z-mutat fold improperli accumul
hepatocyt lead liver diseas unabl secret result lower level serum lung
decreas z-aat molecul polymer lung becom chemo-attract neutrophil misfold er stress
respons observ varieti diseas includ cystic fibrosi cf target cellular fold
cellular proteostasi pathway approach use aatd cf plo biol
vitro assay z-mutant secret histon deacetylas hdac inhibitor suberoylanilid hydroxam acid
saha shown restor z- secret serpin activ approxim wild-typ level biol
chem directli classic librari screen silico model use identifi chemic
chaperon bind z-aat improv fold escap er articl publish report activ
uniqu inhibitor z-aat polymer abl bind z-aat molecul
prevent polymer sever strategi prevent polymer mutat form evalu
discuss follow review pediatr although agent abl prevent
polymer abl yield suffici level secret biolog function lung
redox statu may diseas modifi factor sever studi shown oxid stress featur
aatd may associ pathophysiolog diseas earli stage respir cell mol biol
specif data present suggest cigarett smoke acceler polymer z-aat
oxid modif result increas neutrophil influx lung moreov rat studi n-acetylcystein
shown attenu damag induc elastas support hypothesi oxidant-induc injuri contribut
factor ne-medi emphysema chest final resveratrol treatment shown affect
cigarett smoke-medi gsh deplet protect epitheli cell mediat post-transl modif
 physiol lung cell mol physiol thu increas oxid stress could contribut higher
risk lung damag would support use antioxid therapi treatment aatd
model updat updat model reflect manag guidanc revenu front lower
full year cf product revenu forecast compani guidanc per manag
cf revenu would mainli driven three factor symdeko symkevi launch symdeko label expans new
reimburs agreement us addit would expect neg impact cf revenu channel
inventori build occur end higher gross net adjust typic occur
first quarter year accord manag neg impact may off-set new patient growth first
quarter total cf revenu could sequenti lower result lower cf revenu
project vs oper expens front compani expect total
sg expens larg driven cf develop effort increment invest support potenti launch tripl
regimen invest expand pipelin addit diseas maintain forecast total sg
expens within guid rang lastli start regist tax
tax rate compani guidanc note vast major compani tax provis non-
cash expens nol fulli util
number wednesday compani report total revenu fourth quarter
whole year research develop cost quarter year sell gener
administr expens quarter whole year compani report net incom
quarter year decemb compani
cash cash equival
valuat risk invest thesi price target base equal weight composit
multipl tax dilut ep discount back
 npv discount rate termin growth rate risk invest thesi target price
includ failur kalydeco orkambi tezacaftor combin clinic studi
failur kalydeco orkambi symdeko achiev peak sale revenu product competit
mm except per share valu
total orkambi revenu
incivo royalti janssen
hiv proteas inhibitor royalti gsk
revenu
revenu
revenu
revenu
revenu
chang fair valu deriv instrument
provis incom tax
loss attribut non-controlling interest
dcf analysi flow valu ms
chang work capit
materi confidenti intend use institut account defin finra rule may also
privileg otherwis protect work product immun legal rule receiv mistak pleas let
us know email repli delet system may copi messag
disclos content anyon integr secur messag guarante internet
 wainwright co llc rate wainwright employ three tier rate system evalu
potenti return risk associ own common equiti share rate firm expect return given
equiti measur rel basi compani sector price object calcul estim
potenti movement price given equiti could reach provid certain target met defin time horizon
price object subject extern factor includ industri event market volatil
market outperform buy common stock compani expect outperform passiv index compris
common stock compani within sector
market perform neutral common stock compani expect mimic perform passiv index
compris common stock compani within sector
market under-perform sell common stock compani expect under-perform passiv index compris
common stock compani within sector
rate price target histori inc vrtx-u
invest bank servic includ limit act manager/co-manag underwrit placement
secur act financi advisor and/or provid corpor financ capit markets-rel servic compani
one affili subsidiari within past month
distribut rate tabl februari
 wainwright co llc firm member finra sipc regist broker-deal
andrew fein alicia yin ph li wang watsek certifi view express report accur
reflect person view subject secur issuer discuss part compens
directli indirectli relat specif recommend view express research report neither
member household offic director advisori board member compani
none research analyst research analyst household financi interest secur vertex
pharmaceut inc includ without limit option right warrant futur long short posit
januari neither firm affili benefici class common equiti secur
neither research analyst firm materi conflict interest research analyst know
reason know time public research report
research analyst princip respons prepar report receiv compens base upon
specif invest bank servic transact compens base factor includ total revenu profit
firm substanti portion deriv invest bank servic
firm affili receiv compens inc invest bank servic within
twelv month seek compens compani mention report invest bank servic
within three month follow public research report
firm make market date research report
secur compani discuss report may unsuit investor depend specif invest
object financi posit past perform guarante futur result report offer inform
purpos constitut offer solicit buy sell secur discuss herein jurisdict
would prohibit research report intend provid tax advic use provid tax advic
person electron version wainwright co llc research report made avail client simultan
part report may reproduc form without express permiss wainwright co llc addit
 wainwright co llc provid individu tailor invest advic research report research report
intend provid person invest advic take account specif invest object financi
situat particular need specif person investor seek financi advic regard appropri
invest financi instrument implement invest strategi discuss recommend research report
 wainwright co llc affili salespeopl trader profession may provid oral written market
commentari trade strategi reflect opinion contrari opinion express research report
 wainwright co llc affili offic director employe exclud analyst time time
long short posit act princip buy sell secur deriv includ option warrant
thereof cover compani refer research report
inform contain herein base sourc believ reliabl guarante us
accur purport complet statement summari avail data compani industri secur
discuss report opinion estim includ report constitut analyst judgment date
report subject chang without notic
secur financi instrument discuss research report may lose valu insur feder
deposit insur corpor subject invest risk includ possibl loss princip amount invest
